CAJ | 학술논문

目的:评价慢性粒细胞白血病慢性期患者接受伊马替尼治疗的临床效果及不良反应.方法:慢性粒细胞白血病慢性期患者114例,随机分为观察组(69例)和对照组(45例)两组.观察组患者采用伊马替尼进行治疗,对照组则采用干扰素进行治疗,对比两组患者的临床治疗效果.结果:观察组患者治疗3个月完全血液学缓解率(95.65%)、6个月部分细胞遗传学缓解率(82.61%)、12个月完全细胞遗传学缓解率(79.71%)、18个月主要分子学缓解率(68.12%)与对照组(75.55%、33.33%、22.22%、0%)比较差异具有统计学意义(P<0.05).两组不良反应比较,观察组的不良反应较轻,安全性要高于对照组,差异具有统计学意义(P<0.05).观察组五年的总生存率为97.10%,无事件生存率为91.30%,与对照组的82.22%、73.33%比较,差异具有统计学意义(P<0.05).结论:伊马替尼治疗能明显提高慢性粒细胞白血病慢性期患者的细胞遗传学和分子学疗效,不良反应少,可延长无疾病进展生存期.
목적:평개만성립세포백혈병만성기환자접수이마체니치료적림상효과급불량반응.방법:만성립세포백혈병만성기환자114례,수궤분위관찰조(69례)화대조조(45례)량조.관찰조환자채용이마체니진행치료,대조조칙채용간우소진행치료,대비량조환자적림상치료효과.결과:관찰조환자치료3개월완전혈액학완해솔(95.65%)、6개월부분세포유전학완해솔(82.61%)、12개월완전세포유전학완해솔(79.71%)、18개월주요분자학완해솔(68.12%)여대조조(75.55%、33.33%、22.22%、0%)비교차이구유통계학의의(P<0.05).량조불량반응비교,관찰조적불량반응교경,안전성요고우대조조,차이구유통계학의의(P<0.05).관찰조오년적총생존솔위97.10%,무사건생존솔위91.30%,여대조조적82.22%、73.33%비교,차이구유통계학의의(P<0.05).결론:이마체니치료능명현제고만성립세포백혈병만성기환자적세포유전학화분자학료효,불량반응소,가연장무질병진전생존기.
Objective: To investigate the clinical effect imatinib treatment of patients with chronic myeloid leukemia in chronic phase. Methods: 114 patients with chronic myeloid leukemia in chronic phase were randomly divided into an observation group (69 cases) and a control group (45 cases). The observation group was treated with imatinib and the control group was treated with interferon. The clinical treatment effect of the two groups was compared. Results: Regarding the observation group, the rate of the complete hematologic response (CHR) of patients treated for 3 months was 95.65%, the rate of the part cytogenetic response (PCyR) of patients treated for 6 months was 82.61%, the rate of the complete cytogenetic response (CCyR) of patients treated for 12 months was 79.71%, and the rate of the main molecular response (MMR) was 68.12%. Regarding the control group, the rate of the complete hematologic response, the part cytogenetic response, the complete cytogenetic response, and he main molecular response were 75.55%, 33.33%, 22.22%, and 0% respectively. Comparison of these rates between the two groups shows that there were significant difference (P<0.05). Comparison of the adverse reactions between the two groups shows that the adverse reactions in the observation group was lighter than that in the control group and the difference was statistically significant (P<0.05). The 5-year overall survival (OS) of the observation group was 97.10% and the rate of progression-free survival (PES) 91.30%. Compared with that of the control group (82.22%, and 73.33% respectively), the difference was statistically significant (P<0.05). Conclusion: Imatinib treatment for the patients with chronic myeloid leukemia in chronic phase, can improve the molecular reaction and the cytogenetic response with fewer side effects, and it can prolong the survival of non-disease progression.